CagriSema — Semaglutide + Cagrilintide Combination

Type: drug

Status: NDA expected 2026

Developer: Novo Nordisk

Breakthrough Summary

Combination of semaglutide and cagrilintide in a single weekly injection. Phase 3 data shows superior weight loss (up to 22%) and HbA1c reduction compared to semaglutide alone.

Mechanism of Action

Combination of semaglutide (GLP-1) and cagrilintide (amylin analog) in a single weekly injection

Year: 2025-2026